Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LATS1 | O95835 | 1/20 | 0.39 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.36 |
| ▸ | FYN | P06241 | 2/20 | 0.36 |
| ▸ | CDK1 | P06493 | 4/20 | 0.36 |
| ▸ | KDR | P35968 | 4/20 | 0.36 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | CDK2 | P24941 | 3/20 | 0.36 |
| ▸ | CDK9 | P50750 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2818636 | 1.00 | MEN1 (0.45) | MEN1KMT2AKDM4EALDH1A1POLB | |
| SCHEMBL14367850 | 1.00 | MEN1 (0.45) | MEN1KMT2AKDM4EALDH1A1POLB | |
| SCHEMBL4188946 | 0.91 | MEN1 (0.49) | MEN1KMT2AALDH1A1LATS1LATS2 | |
| SCHEMBL13649001 | 0.91 | MEN1 (0.43) | MEN1KMT2AKDM4EALDH1A1POLB | |
| SCHEMBL13649035 | 0.86 | MEN1 (0.40) | MEN1KMT2AKDM4EMAPTCDK1 | |
| SCHEMBL14355520 | 0.86 | MEN1 (0.40) | MEN1KMT2AKDM4EMAPTCDK1 | |
| SCHEMBL1937589 | 0.85 | KDM4E (0.45) | MEN1KMT2AKDM4EALDH1A1POLB | |
| SCHEMBL13649023 | 0.85 | MEN1 (0.40) | MEN1KMT2ACRHR1CDK1KDR | |
| SCHEMBL28723217 | 0.84 | KDM4E (0.43) | MEN1KMT2AKDM4EALDH1A1POLB | |
| SCHEMBL29607551 | 0.84 | KDM4E (0.43) | MEN1KMT2AKDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825128-B2 | Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs | BAYER SCHERING PHARMA AG (DE) | 2010-11-02 | — | — | US | disclosed |
| US-7598260-B2 | CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-10-06 | — | — | US | disclosed |
| US-7598260-B2 | CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-10-06 | — | — | US | disclosed |
| EP-1963282-A1 | SULFOXIMINE-SUBSTITUTED PYRIMIDINES , THEIR PREPARATION AND USE AS DRUGS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-09-03 | — | — | EP | disclosed |
| US-20080039447-A1 | CDK-Inhibitory pyrimidines, their production and use as pharmaceutical agents | BRUMBY THOMAS | 2008-02-14 | — | — | US | disclosed |
| US-20080039447-A1 | CDK-Inhibitory pyrimidines, their production and use as pharmaceutical agents | BRUMBY THOMAS | 2008-02-14 | — | — | US | disclosed |
| US-7291624-B2 | CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AG (DE) | 2007-11-06 | — | — | US | disclosed |
| US-7291624-B2 | CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AG (DE) | 2007-11-06 | — | — | US | disclosed |
| US-7288547-B2 | CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2007-10-30 | — | — | US | disclosed |
| US-7288547-B2 | CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2007-10-30 | — | — | US | disclosed |
| US-7288547-B2 | CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2007-10-30 | — | — | US | disclosed |
| US-20070232632-A1 | Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| WO-2007071455-A1 | SULFOXIMINE-SUBSTITUTED PYRIMIDINES , THEIR PREPARATION AND USE AS DRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-06-28 | — | — | WO | disclosed |
| US-7235561-B2 | Compound and a composition including such a compound | SCHERING AG (DE) | 2007-06-26 | — | — | US | disclosed |
| US-7235561-B2 | Compound and a composition including such a compound | SCHERING AG (DE) | 2007-06-26 | — | — | US | disclosed |
| US-20040063737-A1 | CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063737-A1 | CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents | CDK2, CDK6, CDKL2 | MEN1 3196/4885KMT2A 634/4885KDM4E 694/4885 |
| US-20080039447-A1 | CDK-Inhibitory pyrimidines, their production and use as pharmaceutical agents | CDK2, CDK1, CDK6 | MEN1 3298/4885KMT2A 873/4885KDM4E 767/4885 |
| US-20070232632-A1 | Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs | TYMS, DPYD, DHFR | MEN1 3313/4885KMT2A 4091/4885KDM4E 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.